List view / Grid view
11 April 2025 | By Drug Target Review
Our editorial webinars provide free access to expert insights from leading scientists and industry professionals, offering high-quality educational content that serves as a valuable resource. These webinars generate hundreds of leads, providing a straightforward way to engage your target audience. By submitting your company’s logo, you'll receive full access to…
Drug development is plagued by high costs, long timelines and low success rates, but what if AI could change that? Read on to discover real-world examples and explore the transformative potential of AI in drug development.
In this interview with Jose-Manuel Collados, learn how ABB's strategic partnerships and automation technology are improving lab efficiency, enhancing precision and ultimately speeding up the development of life-saving treatments.
In this second part of a two-part series, we continue Sujeegar Jeevanandam’s exploration of the future of AI in drug discovery. We share his vision for transformative AI applications, such as simulating human pharmacokinetics and pharmacodynamics, and offer strategic recommendations for biotechs looking to adopt AI.
Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
AI is transforming drug discovery, but its adoption mirrors past technological shifts in the industry. In this first part of a two-part series, we reveal Sujeegar Jeevanandam’s observations of the parallels between AI and the electronic lab notebook revolution, highlighting key challenges, lessons learned, and what the future holds for…
AI-driven drug development, powered by advanced models and expanding data access, is becoming a reality. Learn why navigating regulatory hurdles and mastering biology’s inherent complexities are crucial to fully unlocking its potential.
ElevateBio is teaming up with Amazon Web Services (AWS) to advance CRISPR gene editing using AI and cloud computing. This collaboration aims to accelerate drug discovery for genetic diseases, making next-generation therapies more efficient and accessible.
Google has introduced an AI-powered 'co-scientist' designed to accelerate biomedical research and drug discovery by generating scientific hypotheses and identifying novel therapeutic targets.
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
Researchers at Mount Sinai have created a computational tool that predicts effective drug combinations, providing a faster and more cost-efficient method for identifying potential treatments for complex diseases like cancer.
The FORESIGHT consortium has secured €9 million to speed up drug development using advanced molecular imaging, targeting major diseases like cancer, autoimmune conditions, and heart disorders.
In this article, Dr Raminderpal Singh explores the transformative impact of the Deepseek R1 open-source large language model on drug discovery. Its potential offers exciting opportunities for both scientists and software developers, marking a significant advancement for the life sciences community.
Capgemini's new AI-powered methodology reduces data requirements by 99 percent and accelerates bioengineering breakthroughs, including improved plastic degradation and faster drug discovery.
How are clinical genomics and AI transforming drug development? Industry experts reveal how these technologies improve target identification, patient stratification, and trial design to drive higher success rates.
